Prothena Q3 net loss narrows to $36.5 mln

Prothena

06/11/2025 21:58

Overview

Prothena Q3 2025 net loss narrowed to $36.5 mln, with collaboration revenue of $2.4 mln

Company highlighted Phase 3 trials for prasinezumab and coramitug

Prothena to hold EGM for potential share redemption program in 2026

Outlook

Prothena expects 2025 net cash use of $170 to $178 mln

Company anticipates ending 2025 with $298 mln in cash

Prothena plans share redemption program vote in Nov 2025

Result Drivers

R&D EXPENSES - Decrease in R&D expenses attributed to lower clinical trial and personnel costs

COLLABORATION REVENUE - Revenue primarily from Bristol Myers Squibb collaboration related to PRX019 Phase 1 trial

CASH POSITION - Strong cash position supports pipeline advancement

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$2.42 mln
Q3 Net Income
-$36.54 mln
Q3 Operating Expenses
$42.66 mln
Q3 Pretax Profit
-$36.91 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Prothena Corporation PLC is $14.50, about 29.2% above its November 5 closing price of $10.27

Press Release: ID:nBw7Py0DGa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)